Eikon Therapeutics Inc
Research Eikon Therapeutics Inc (EIKN) on Bullrun: market cap USD 404.49M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEIKN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 404.49M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 88.41M
- Free cash flow-USD 65.21M
Valuation Snapshot
latest market cap is USD 404.49M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 324.25M | -USD 235.26M | n/a | -6.18 | USD 104.90M | USD 257.32M | -USD 879.03M |
| FY2024 | USD 0 | -USD 243.81M | -USD 219.60M | n/a | -7.45 | USD 129.18M | USD 202.46M | -USD 571.93M |
| FY2023 | USD 0 | -USD 242.00M | -USD 219.36M | n/a | -7.4 | USD 112.78M | USD 31.74M | -USD 341.37M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 404.49M | n/a | n/a | n/a |
About Eikon Therapeutics Inc
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Eikon Therapeutics Inc's market cap?
Eikon Therapeutics Inc's market capitalization is USD 404.49M.
What does Eikon Therapeutics Inc do?
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs.